Browsing by Author Wilson, Kate

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)Citation
2010Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study.Gebski, Val; Simes, Robert John; Stockler, Martin; Zannino, Diana; Ackland, Stephen P.; Broad, Adam; Chua, Yu Jo; Cummins, Michelle; Cunningham, David; Forgeson, Garry; Ganju, Vinod; Price, Timothy; Robinson, Bridget; Saunders, M; Tebbutt, Niall C; van Hazel, Guy; Wilson, Kate; Zalcberg, J; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCapecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study., Journal of Clinical Oncology (Online), vol.28, 19,pp 3191-3198
2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerGebski, Val; Lee, Chee Khoon; Mann, Kristy; Simes, Robert John; Wilson, Kate; Bruhn, M; Cunningham, David; Hardingham, Jennifer; Price, Timothy; Robinson, B; Tebbutt, Niall; Townsend, Amanda; van Hazel, Guy; Weickhardt, Andrew; Wrin, Joseph; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreCorrelation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer, British Journal of Cancer, vol.112, 6, 2015,pp 963-970
2015Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: The ALaCaRT randomized clinical trialDavies, Lucy; Gebski, Val; Hague, Wendy; Simes, Robert John; Solomon, Michael; Wilson, Kate; Clouston, Andrew; Hewett, Peter; Lumley, John; Stevenson, Andrew R. L.; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Central Clinical School: Surgery; NH&MRC Clinical Trials CentreEffect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: The ALaCaRT randomized clinical trial, JAMA: The Journal of the American Medical Association, vol.314, 13, 2015,pp 1356-1363
2014Final results of Australasian Gastrointestinal Trials Group ARCTIC study: An audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidinesFournier, Marion; Gebski, Val; Simes, Robert John; Wilson, Kate; Ferry, David; Gordon, Stuart; Karapetis, Christos; Price, Timothy; Ransom, David; Tebbutt, Niall; Yip, Desmond; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreFinal results of Australasian Gastrointestinal Trials Group ARCTIC study: An audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines, Annals of Oncology, vol.25, 1, 2014,pp 117-121
2016ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursGebski, Val; Khasraw, Mustafa; Pavlakis, Nick; Thavaneswaran, Subotheni; Wilson, Kate; Chantrill, Lorraine A; Day, Fiona; Desai, Jayesh; Elez, Elena; et al, Various; Jefford, Michael; Nott, Louise M; Segelov, Eva; Underhill, Craig; Waring, Paul; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours, BMC Cancer, vol.16, 1, 2016,pp 1-8
2008Improving Undergraduate Laboratory Work in Physics: Outcomes of the ‘Forging new directions in physics education in Australian universities’ Project.Sharma, Manjula; Kirkup, Les; Mendez, Alberto; Mills, David; Wilson, Kate; PhysicsImproving Undergraduate Laboratory Work in Physics: Outcomes of the ‘Forging new directions in physics education in Australian universities’ Project., Australian Institute of Physics 18th National Congress - Refereed Papers, vol.N/A,(),2008,pp 155-158
2016MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trialWilson, Kate; Coscia, Claudio; Gormly, Kirsten; Harvey, Jennifer A; Price, Timothy; Schmoll, Hans-Joachim; Tebbutt, Niall; Wells, Tim; NH&MRC Clinical Trials CentreMRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial, Journal of Medical Imaging and Radiation Oncology, vol.60, 5, 2016,pp 607-615
2016MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trialWilson, Kate; Coscia, Claudio; Gormly, Kirsten; Harvey, Jennifer A; Price, Timothy; Schmoll, Hans-Joachim; Tebbutt, Niall; Wells, Tim; NH&MRC Clinical Trials CentreMRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial, Journal of Medical Imaging and Radiation Oncology, vol.60, 5, 2016,pp 607-615
2016Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM StudyGebski, Val; Khasraw, Mustafa; Pavlakis, Nick; Robledo, Kristy; Simes, Robert John; Thavaneswaran, Subotheni; Wilson, Kate; Chantrill, Lorraine A; Desai, Jayesh; Elez, Elena; et al, Various; Karapetis, Christos (Chris); Lunke, Sebastian; Nott, Louise M; Segelov, Eva; Underhill, Craig; Waring, Paul; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; School of Molecular Bioscience (SMB)Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study, Journal of Clinical Oncology, vol.34, 19, 2016,pp 2258-2264
2011Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumabCummins, Michelle; Marx, Gavin; Shannon, Jenny; Simes, Robert John; Wilson, Kate; Zannino, Diana; Abdi, Ehtesham A; Blum, R; Chantrill, L; Goldstein, D; Karapetis, Christos; Lowenthal, Raymond M.; Murphy, F; Nayagam, S; Price, Timothy; Strickland, A. H.; Tebbutt, Niall C; School of Public Health: NH&MRC Clinical Trials Centre; Medicine; Nepean Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRisk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab, Annals of Oncology, vol.22, 8, 2011,pp 1834-1838